Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Acorda Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
ESTEVE Launches INBRIJA® in Spain
Details : Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 07, 2023
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Acorda Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Acorda Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Esteve Launches INBRIJA® in Germany
Details : INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibito...
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 16, 2022
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Acorda Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Acorda Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany
Details : Under the agreement, ESTEVE will have the exclusive distribution rights to INBRIJA in Germany and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Germany by mid-2022.
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : $5.6 million
November 09, 2021
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Acorda Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Acorda Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
Details : Under the terms of the supply agreement, ACORDA will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 22, 2021
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Acorda Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.
Brand Name : E-58425
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 03, 2021
Lead Product(s) : Celecoxib,Tramadol Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Kowa Pharmaceuticals America
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?